142 related articles for article (PubMed ID: 20200999)
1. Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion.
Bertoldo F; Pancheri S; Zenari S; Boldini S; Giovanazzi B; Zanatta M; Valenti MT; Dalle Carbonare L; Lo Cascio V
J Bone Miner Res; 2010 Mar; 25(3):447-54. PubMed ID: 20200999
[TBL] [Abstract][Full Text] [Related]
2. ACUTE PHASE REACTIONS AFTER ZOLEDRONIC ACID INFUSION: PROTECTIVE ROLE OF 25-HYDROXYVITAMIN D AND PREVIOUS ORAL BISPHOSPHONATE THERAPY.
Crotti C; Watts NB; De Santis M; Ceribelli A; Fabbriciani G; Cavaciocchi F; Marasini B; Selmi C; Massarotti M
Endocr Pract; 2018 May; 24(5):405-410. PubMed ID: 29498910
[TBL] [Abstract][Full Text] [Related]
3. Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction.
De Santis M; Cavaciocchi F; Ceribelli A; Crotti C; Generali E; Fabbriciani G; Selmi C; Massarotti M
Lupus; 2015 Apr; 24(4-5):442-7. PubMed ID: 25801887
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
Popp AW; Senn R; Curkovic I; Senn C; Buffat H; Popp PF; Lippuner K
Osteoporos Int; 2017 Jun; 28(6):1995-2002. PubMed ID: 28299378
[TBL] [Abstract][Full Text] [Related]
5. Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass.
Anastasilakis AD; Polyzos SA; Makras P; Sakellariou GT; Bisbinas I; Gkiomisi A; Delaroudis S; Gerou S; Ballaouri I; Oikonomou D; Papapoulos SE
Bone; 2012 May; 50(5):1130-4. PubMed ID: 22366634
[TBL] [Abstract][Full Text] [Related]
6. Preventive Role of Vitamin D Supplementation for Acute Phase Reaction after Bisphosphonate Infusion in Paget's Disease.
Merlotti D; Rendina D; Muscariello R; Picchioni T; Alessandri M; De Filippo G; Materozzi M; Bianciardi S; Franci MB; Lucani B; Cenci S; Strazzullo P; Nuti R; Gennari L
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31634910
[TBL] [Abstract][Full Text] [Related]
7. Increased Serum 25(OH)D
Nakamura Y; Uchiyama S; Kamimura M; Ikegami S; Komatsu M; Kato H
Tohoku J Exp Med; 2017 Jul; 242(3):241-246. PubMed ID: 28740036
[TBL] [Abstract][Full Text] [Related]
8. [Acute phase reaction following bisphosphonates.].
Tsurukami H
Clin Calcium; 2017; 27(2):213-223. PubMed ID: 28123123
[TBL] [Abstract][Full Text] [Related]
9. Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration.
Rossini M; Adami S; Viapiana O; Ortolani R; Vella A; Fracassi E; Gatti D
J Bone Miner Res; 2012 Jan; 27(1):227-30. PubMed ID: 21956654
[TBL] [Abstract][Full Text] [Related]
10. No effect of rosuvastatin in the zoledronate-induced acute-phase response.
Makras P; Anastasilakis AD; Polyzos SA; Bisbinas I; Sakellariou GT; Papapoulos SE
Calcif Tissue Int; 2011 May; 88(5):402-8. PubMed ID: 21305270
[TBL] [Abstract][Full Text] [Related]
11. 25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis.
Peris P; Martínez-Ferrer A; Monegal A; Martínez de Osaba MJ; Muxi A; Guañabens N
Bone; 2012 Jul; 51(1):54-8. PubMed ID: 22487299
[TBL] [Abstract][Full Text] [Related]
12. Characterization of and risk factors for the acute-phase response after zoledronic acid.
Reid IR; Gamble GD; Mesenbrink P; Lakatos P; Black DM
J Clin Endocrinol Metab; 2010 Sep; 95(9):4380-7. PubMed ID: 20554708
[TBL] [Abstract][Full Text] [Related]
13. Association between vitamin D and zoledronate-induced acute-phase response fever risk in osteoporotic patients.
Lu K; Shi Q; Gong YQ; Li C
Front Endocrinol (Lausanne); 2022; 13():991913. PubMed ID: 36299453
[TBL] [Abstract][Full Text] [Related]
14. The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass.
Anastasilakis AD; Polyzos SA; Delaroudis S; Bisbinas I; Sakellariou GT; Gkiomisi A; Papadopoulou E; Gerou S; Makras P
Clin Endocrinol (Oxf); 2012 Dec; 77(6):816-22. PubMed ID: 22676573
[TBL] [Abstract][Full Text] [Related]
15. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.
Deane A; Constancio L; Fogelman I; Hampson G
BMC Musculoskelet Disord; 2007 Jan; 8():3. PubMed ID: 17214897
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of amino-bisphosphonates on circulating γδ T cells.
Rossini M; Adami S; Viapiana O; Fracassi E; Ortolani R; Vella A; Zanotti R; Tripi G; Idolazzi L; Gatti D
Calcif Tissue Int; 2012 Dec; 91(6):395-9. PubMed ID: 23052225
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis.
Catalano A; Morabito N; Atteritano M; Basile G; Cucinotta D; Lasco A
Calcif Tissue Int; 2012 Apr; 90(4):279-85. PubMed ID: 22350110
[TBL] [Abstract][Full Text] [Related]
18. Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women.
Thompson K; Keech F; McLernon DJ; Vinod K; May RJ; Simpson WG; Rogers MJ; Reid DM
Bone; 2011 Jul; 49(1):140-5. PubMed ID: 21047568
[TBL] [Abstract][Full Text] [Related]
19. The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml.
Carmel AS; Shieh A; Bang H; Bockman RS
Osteoporos Int; 2012 Oct; 23(10):2479-87. PubMed ID: 22237813
[TBL] [Abstract][Full Text] [Related]
20. Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment.
Anastasilakis AD; Polyzos SA; Makras P; Savvides M; Sakellariou GT; Gkiomisi A; Papatheodorou A; Terpos E
Horm Metab Res; 2014 Feb; 46(2):145-9. PubMed ID: 23918682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
